Formulation Development
MilliporeSigma Launches BioContinuum Seed Train Platform for Intensified Upstream Processes
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, recently announced at the ESACT meeting…
Mogrify & Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss
Mogrify Limited and Astellas Pharma Inc. recently announced they have executed a collaborative research agreement on in vivo regenerative medicine approaches to….
Codiak BioSciences & CEPI Partner to Develop Broadly Protective Betacoronavirus Vaccine
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences recently announced the latest funding award under CEPI’s US $200 million program to advance the development of vaccines that provide broad protection against….
Fastox to Present its Long-Lasting Botulinum Toxin LAST Technology
Swiss biotech Fastox Pharma will present for the first time its groundbreaking long-lasting botulinum toxin LAST technology at the leading conference on neurotoxins from July…
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial
Fulcrum Therapeutics, Inc. recently announced the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and efficacy…
DFE Pharma Expands its Inhalation Portfolio With New Launch
DFE Pharma recently announced the expansion of its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale 400. The addition of Lactohale 400 further enhances the completeness of DFE Pharma’s portfolio of inhalation-grade lactose…..
Evonik Launches Non-Animal-Derived Collagen Platform at Commercial Scale for Medical Device Applications
Evonik’s recombinant, non-animal-derived collagen platform is now available at commercial scale. Vecollan is a highly pure and soluble collagen that is produced via fermentation. It…
BriaCell Partners With Waisman Biomanufacturing to Manufacture & Supply Prostate Cancer Immunotherapy
BriaCell Therapeutics Corp. has recently entered a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison (Waisman), to manufacture Bria-Pros, BriaCell’s off-the-shelf personalized….
Chinook Therapeutics Receives Orphan Drug Designation for BION-1301 for Treatment of Primary IgA Nephropathy
Chinook Therapeutics, Inc. recently announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). The decision…
Cara Therapeutics Announces Positive Topline Results From Phase 2 Trial of Oral Difelikefalin
Cara Therapeutics, Inc. recently announced positive topline results from its Phase 2 proof-of-concept clinical trial (KOMFORT) evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in….
BioCorRx Announces First Subject Dosed in Phase 1 Clinical Trial of Implantable Naltrexone Pellet
BioCorRx Inc. recently announced the first subject has been dosed in the Phase 1 clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the…
US Government to Support Expansion of Croda Lipid Systems Capability
Croda International Plc recently announced it has entered into a cooperative agreement with the US government in which the government will provide up to $75 million to expand the….
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
Neurona Therapeutics recently announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study…..
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
AN2 Therapeutics, Inc. recently announced it has screened its first patient in its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex…..
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor
Ventyx Biosciences, Inc. recently announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735, a…
SciSparc Successfully Completed Development of its Proprietary Drug Candidate for Upcoming Phase 2b Study in Tourette Syndrome
SciSparc Ltd. recently announced it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase…
Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate
Ocuphire Pharma, Inc. recently announced the USPTO has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330.…
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
BriaCell Therapeutics Corp. recently announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty…
ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
Roivant and Pfizer Unveil Priovant Therapeutics & Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Roivant Sciences and Pfizer recently announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity…
